K H Heyne1, S M Lippman, J J Lee, J S Lee, W K Hong. 1. Section of Head, Neck, and Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030.
Abstract
PURPOSE AND METHODS: A review of 446 patients who were enrolled consecutively in small-cell lung cancer (SCLC) protocols was performed to identify in long-term survivors the frequency of new primary tumors and their clinical impact. RESULTS: Forty-seven patients (10.5%) were identified to be free of disease at 2 years. Second primary tumors (SPTs) were diagnosed in 14 patients. The overall risk for developing an SPT was 10.3% per person-year. Actuarial risk at 8 years was 50.3% for an SPT. CONCLUSIONS: In this review, SCLC showed one of the highest incidences of SPTs reported in aerodigestive tract malignancies. A long-term survivor was more likely to have an SPT than a relapse of SCLC. Consequently, the odds of death from an SPT compared with that from a relapse increased sharply from 1:13 within 4 years from diagnosis to 8:1 afterwards. Long-term survivors of SCLC would be excellent candidates for chemoprevention trials.
PURPOSE AND METHODS: A review of 446 patients who were enrolled consecutively in small-cell lung cancer (SCLC) protocols was performed to identify in long-term survivors the frequency of new primary tumors and their clinical impact. RESULTS: Forty-seven patients (10.5%) were identified to be free of disease at 2 years. Second primary tumors (SPTs) were diagnosed in 14 patients. The overall risk for developing an SPT was 10.3% per person-year. Actuarial risk at 8 years was 50.3% for an SPT. CONCLUSIONS: In this review, SCLC showed one of the highest incidences of SPTs reported in aerodigestive tract malignancies. A long-term survivor was more likely to have an SPT than a relapse of SCLC. Consequently, the odds of death from an SPT compared with that from a relapse increased sharply from 1:13 within 4 years from diagnosis to 8:1 afterwards. Long-term survivors of SCLC would be excellent candidates for chemoprevention trials.
Authors: W A Franklin; A F Gazdar; J Haney; I I Wistuba; F G La Rosa; T Kennedy; D M Ritchey; Y E Miller Journal: J Clin Invest Date: 1997-10-15 Impact factor: 14.808
Authors: I I Wistuba; S Lam; C Behrens; A K Virmani; K M Fong; J LeRiche; J M Samet; S Srivastava; J D Minna; A F Gazdar Journal: J Natl Cancer Inst Date: 1997-09-17 Impact factor: 13.506
Authors: I I Wistuba; J Berry; C Behrens; A Maitra; N Shivapurkar; S Milchgrub; B Mackay; J D Minna; A F Gazdar Journal: Clin Cancer Res Date: 2000-07 Impact factor: 12.531
Authors: Summer S Han; Gabriel A Rivera; Martin C Tammemägi; Sylvia K Plevritis; Scarlett L Gomez; Iona Cheng; Heather A Wakelee Journal: J Clin Oncol Date: 2017-06-23 Impact factor: 44.544
Authors: Jacqueline V Aredo; Natasha Purington; Li Su; Sophia J Luo; Nancy Diao; David C Christiani; Heather A Wakelee; Summer S Han Journal: Lung Cancer Date: 2021-03-11 Impact factor: 5.705